Released on = June 20, 2007, 3:15 pm

Press Release Author = AnaSpec Inc.

Industry = Biotech

Press Release Summary = Leveraging one of the world's largest collections of amyloid
peptides, AnaSpec has introduced its latest development in novel solutions for
amyloid-related research - the new SensoLyteT 520 Beta-Secretase Assay Kit.

Press Release Body = June 18, 2007 - San Jose, CA

Leveraging one of the world's largest collections of amyloid peptides, AnaSpec has
introduced its latest development in novel solutions for amyloid-related research -
the new SensoLyteT 520 Beta-Secretase Assay Kit.
Beta-secretase catalyzes a key step in the production of beta-amyloid peptides seen
accumulated in senile plagues of Alzheimer's disease (AD) brains. In order to
facilitate high throughput screening of AD drug candidates, we have developed a new
SensoLyteT 520 beta-secretase assay kit using a fluorescence resonance energy
transfer (FRET) peptide, HiLyte FluorT 488-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(QXLT
520)-OH (see Figure 1). The sequence of this FRET peptide is derived from the
beta-secretase cleavage site of beta-amyloid precursor protein(APP) with Swedish
mutation.6 This mutation enhances the susceptibility of APP to beta-secretase and
results in an early onset of AD.

This assay has good sensitivity (0.03 mU/ml) with a signal-to-background ratio >10
after a 30-minute incubation. This homogeneous assay can be used to continuously
monitor product formation. Validated with known inhibitors, the IC50 value for one
of the inhibitors determined with SensoLyteT 520 beta-secretase assay kit was
consistent with published data.

Fore more information, visit http://www.anaspec.com/products/productcategory.asp?id

Web Site = http://www.anaspec.com

Contact Details = ping@anaspec.com